OTCPK:SHTPY (Germany)
Â
ADR
$
4.37
-3.28 (-42.88%)
08:08 PM EST
Business Description
Schott Pharma AG & CO KGaA
ISIN : US8080381036
Share Class Description:
SHTPY: ADRTotal Employee Number:
4,839Description
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.29 | |||||
Interest Coverage | 9.8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.57 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.3 | |||||
3-Year EBITDA Growth Rate | 9.9 | |||||
3-Year EPS without NRI Growth Rate | 3.2 | |||||
3-Year FCF Growth Rate | 6.1 | |||||
3-Year Book Growth Rate | 8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.34 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 0.01 | |||||
6-1 Month Momentum % | -42.88 | |||||
12-1 Month Momentum % | -30.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.59 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 0.08 | |||||
Days Inventory | 94.45 | |||||
Days Sales Outstanding | 67.8 | |||||
Days Payable | 43.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 1.11 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.96 | |||||
Operating Margin % | 18.15 | |||||
Net Margin % | 14.45 | |||||
EBITDA Margin % | 29 | |||||
FCF Margin % | 5.84 | |||||
OCF Margin % | 20.35 | |||||
ROE % | 16.05 | |||||
ROA % | 9.13 | |||||
ROIC % | 11.61 | |||||
3-Year ROIIC % | 4.01 | |||||
ROC (Joel Greenblatt) % | 26.23 | |||||
ROCE % | 17.8 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.27 | |||||
Forward PE Ratio | 14.19 | |||||
PE Ratio without NRI | 18.27 | |||||
PEG Ratio | 1.07 | |||||
PS Ratio | 2.63 | |||||
PB Ratio | 2.77 | |||||
Price-to-Tangible-Book | 2.88 | |||||
Price-to-Free-Cash-Flow | 43.73 | |||||
Price-to-Operating-Cash-Flow | 12.83 | |||||
EV-to-EBIT | 13.2 | |||||
EV-to-Forward-EBIT | 11.38 | |||||
EV-to-EBITDA | 9.29 | |||||
EV-to-Forward-EBITDA | 7.75 | |||||
EV-to-Revenue | 2.7 | |||||
EV-to-Forward-Revenue | 2.09 | |||||
EV-to-FCF | 45.62 | |||||
Price-to-GF-Value | 0.62 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.05 | |||||
Price-to-Graham-Number | 1.53 | |||||
Earnings Yield (Greenblatt) % | 7.58 | |||||
FCF Yield % | 2.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHTPY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Schott Pharma AG & CO KGaA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,154.209 | ||
| EPS (TTM) ($) | 0.277 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 49.71 | ||
| 14-Day RSI | 0.01 | ||
| 14-Day ATR ($) | 0.000028 | ||
| 20-Day SMA ($) | 4.37 | ||
| 12-1 Month Momentum % | -30.63 | ||
| 52-Week Range ($) | 4.37 - 7.65 | ||
| Shares Outstanding (Mil) | 602.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Schott Pharma AG & CO KGaA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Schott Pharma AG & CO KGaA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.052957 Cash Dividend | 2026-02-05 | 4.37 (+0.00%) | ||
| USD 0.041360 Cash Dividend | 2025-02-06 | 11.99 (+0.00%) |
Show
Entries
Schott Pharma AG & CO KGaA Frequently Asked Questions
What is Schott Pharma AG & CO KGaA(SHTPY)'s stock price today?
The current price of SHTPY is $4.37. The 52 week high of SHTPY is $7.65 and 52 week low is $4.37.
When is next earnings date of Schott Pharma AG & CO KGaA(SHTPY)?
The next earnings date of Schott Pharma AG & CO KGaA(SHTPY) is .
Does Schott Pharma AG & CO KGaA(SHTPY) pay dividends? If so, how much?
Schott Pharma AG & CO KGaA(SHTPY) does not pay dividend.
Guru Commentaries on OTCPK:SHTPY
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Schott Pharma AG & CO KGaA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers